Clinical Trials
14 trialsNCT02776436 2026-02-17
REDEX
Leiden University Medical Center
Phase 1 Completed
NCT02473042 2025-12-05
Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
M.D. Anderson Cancer Center
Phase NA Completed
NCT03367572 2025-09-25
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester
Phase 3 Completed
NCT04862585 2025-08-20
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Ohio State University Comprehensive Cancer Center
Phase 2/3 Completed
NCT04603911 2025-01-10
RCT Comparing ESPB Solutions in Breast Surgery
Tufts Medical Center
Phase 2 Completed
NCT03125941 2019-12-02
DEX-MAS
Rigshospitalet, Denmark
Phase 4 Completed
NCT02525718 2019-08-14
Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction
Northwestern University
Phase 2 Completed
NCT01332630 2018-09-20
TPI 287 in Breast Cancer Metastatic to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00404066 2017-12-22
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Stanford University
Phase 2 Completed
NCT00343863 2017-07-11
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
University of Washington
Phase NA Completed
NCT00248547 2017-05-09
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
OHSU Knight Cancer Institute
Phase NA Completed
NCT00293384 2016-03-15
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT00475085 2015-11-10
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
University of Rochester
Phase 3 Completed
NCT00580112 2014-02-25
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed